<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260807070565N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-09-13</date_registration>
      <primary_sponsor>Superior university Lahore</primary_sponsor>
      <public_title>Comparison of Dexmedetomidine and Tramadol as Adjuvants to Spinal Anesthesia in Femur Fracture Surgery</public_title>
      <acronym></acronym>
      <scientific_title>The effect of dexmedetomidine versus tramadol as adjuvant in Spinal anesthesia in femur fracture surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-08-15</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>68</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/92299</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: Two-arm, parallel-group randomized controlled clinical trial comparing dexmedetomidine and tramadol as adjuvants to spinal anesthesia in patients undergoing femur fracture surgery, Randomization description: Eligible patients will be individually randomized in a 1:1 ratio into two groups: dexmedetomidine group and tramadol group. A computer-generated randomization sequence will be used to assign patients randomly to either group. Each patient will be assigned a study number and allocated according to the randomization sequence. No stratification or clustering will be used.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Femur fracture.</hc_freetext>
      <i_freetext>Intervention group 1: Patients receiving intrathecal bupivacaine with dexmedetomidine as an adjuvant.Intervention group 2: Patients receiving intrathecal bupivacaine with tramadol as an adjuvant.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Deidentified individual participant data will not be shared because the data are collected for academic thesis purposes and are subject to participant confidentiality and institutional ethical requirements. Data will be accessible only to the research team and authorized supervisors/institutional authorities.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Masaud shah</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Muhalla lahorekheil dheri alladand,district malakand tehsil thana baizai</address>
        <city>Malakand</city>
        <country1>Pakistan</country1>
        <zip>23020</zip>
        <telephone>+92 314 9822371</telephone>
        <email>su91-msahw-f24-069@superior.edu.pk</email>
        <affiliation>Superior university Lahore</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Usra Naeem</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Raiwand road, kot arian, Lahore</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54000</zip>
        <telephone>+92 333 4381978</telephone>
        <email>usra.naeem@superior.edu.pk</email>
        <affiliation>Superior university Lahore</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>patients aged 18-65 yeears
both male and female patients
ASA physical status I or II
Undergoing elective femur fracture surgery under spinal anesthesia
Willing to provide written inform consent</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>contraindications to spinal anesthesia(coagulopathy,local infection,raised ICP)
Known hypersensitivity to dexmedetomidine, tramadol or bupivacaine
ASA physical status III or IV
Significant cardiac, hepatic or renal impairment
Chronic analgesic or opioid abuse</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S72</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fracture of femur</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Patients receiving intrathecal bupivacaine with dexmedetomidine as an adjuvant.Intervention group 2: Patients receiving intrathecal bupivacaine with tramadol as an adjuvant</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Duration of postoperative analgesia. Timepoint: Measured from completion of spinal anesthesia until the first request for rescue analgesia (within the first 24 hours after surgery). Method of measurement: Measured in minutes from intrathecal drug administration to the first rescue analgesic requirement. Pain will be assessed using the Visual Analogue Scale (VAS), and rescue analgesia will be given when VAS ≥4.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Hemodynamic stability (heart rate and mean arterial pressure). Timepoint: Baseline,5,10,15 and 30 minutes after spinal anesthesia. Method of measurement: Measured using a multi parameters monitoring and recorded as heart rate (beat/minute) and mean arterial pressure (mmHg).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Superior university Lahore</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-08-24</approval_date>
        <contact_name>Ethics committee of superior university Lahore</contact_name>
        <contact_address>Raiwand road,kot arian,Lahore Lahore Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
